| Literature DB >> 35669269 |
Marleen M M Swoboda1, Lucie Bartova1, Marlene Dremel1, Ulrich Rabl1, Anton Laggner2, Richard Frey1.
Abstract
QT interval prolongation and ventricular tachyarrhythmia are potential adverse effects of antidepressant (AD) and antipsychotic- (AP) agents, especially when overdosed. Since AD and AP agents are often prescribed to patients suffering from suicidal intentions, it is essential to estimate these risks in the context of intoxications. This retrospective and naturalistic one-year registry study included 105 patients treated for oral intoxication at the University Department of Emergency Medicine in Vienna, Austria. AD/AP intoxications were present in 26 patients, while in the control group (n = 79) non-AD/AP drugs (n = 54) and exclusively alcohol (n = 25) were the toxic agents. QT intervals, the necessity of intubation, the extent of conscious state, and the subsequent discharge management were compared. The mean age was 34.94 ± 14.6 years, 62 patients (59%) were female. There were no significant between-group differences regarding QT prolongation >470 ms using Bazett's correction (p = 0.178), or >440 ms using Fridericia's correction (p = 0.760). No significant group differences concerning the need for intubation were observed (p = 0.747). The AD/AP and the control group did not significantly differ regarding Glasgow Coma Scale scores (p = 0.439). Patients with AD/AP intoxication were significantly more often transferred to the psychiatric department, while discharge to home was more likely in the control group (p = 0.002). These results suggest that the risk of a potentially life-threatening outcome in cases of intoxication with AD/AP is not substantially higher than in other easily available toxic agents, in line with the advantageous risk/benefit ratio of newer ADs and APs.Entities:
Keywords: alcohol; antidepressants; antipsychotics; electrocardiography; emergency psychiatry; toxicity
Year: 2022 PMID: 35669269 PMCID: PMC9165614 DOI: 10.3389/fpsyt.2022.825546
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 5.435
FIGURE 1Comparison between the QT prolongation corrected for heart rate (HR; QT-HR correlation) via (A) Bazett’s correction and (B) Fridericia’s correction . While the QTc intervals are given in milliseconds (ms) and the RR-distances in seconds (s), the heart rate is expressed as beats per minute (bpm).
Individual cases of the AD/AP group.
| AD/AP category | AD/AP substance | Co-intoxication | QTc-B | QTc-F | HR |
| SSRI | Paroxetine, Trazodone | Oxacepam (BZD), Alprazolam (BZD) | 380 ms | 371 ms | 70/min |
| SSRI | Citalopram | Lamotrigine (AC), alcohol | 428 ms | 402 ms | 88/min |
| SSRI | Trazodone | 421 ms | 413 ms | 84/min | |
| SSRI | Trazodone | Hydroxyzine (H1RB), | 437 ms | 430 ms | 72/min |
| SSRI | Trazodone | 476 ms | 458 ms | 75/min | |
| SSRI | Citalopram | Lorazepam (BZD) | 457 ms | 430 ms | 85/min |
| SSRI | Trazodone | 490 ms | 450 ms | 101/min | |
| SSRI, NaSSA | Citalopram, Mirtazapine | 483 ms | 441 ms | 106/min | |
| SSRI, AP | Trazodone, Prothipendyl | Doxepin (AB), alcohol | 468 ms | 433 ms | 95/min |
| NDRI | Bupropion | 505 ms | 464 ms | 101/min | |
| SNRI, AP | Venlafaxine, Tiapride | 424 ms | 416 ms | 66/min | |
| NaSSA | Mirtazapine | Naproxen (NSAID), Metformin (ADM), Flunarizine (CaA) | 440 ms | 413 ms | 89/min |
| AP, NaSSA | Quetiapine, Mirtazapine | Dexibuprofen (NSAID), Mefenamic Acid (NSAID), Propyphenazone (NSAID) | 496 ms | 455 ms | 101/min |
| AP | Prothipendyl, Risperidone | Mefenaminic Acid (NSAID) | 447 ms | 435 ms | 68/min |
| AP | Olanzapine | 475 ms | 421 ms | 126/min | |
| AP | Quetiapine, Risperidone | 446 ms | 408 ms | 105/min | |
| AP | Quetiapine, Chlorprothixene | Lorazepam (BZD) | 466 ms | 421 ms | 113/min |
| AP | Chlorprothixene | 457 ms | 427 ms | 92/min | |
| AP | Prothipendyle | Ramipril (ACE-I), Paracetamol (AN), Pantoprazole (PPI), Bezafibrate (FD), alcohol | 469 ms | 440 ms | 89/min |
| AP | Quetiapine, Olanzapine, Prothipendyl | Oxazepam (BZD) | 467 ms | 444 ms | 83/min |
| AP | Quetiapine, Prothipendyl | 494 ms | 449 ms | 108/min | |
| AP | Chlorprothixene | Nitrazepam (BZD), alcohol | 462 ms | 431 ms | 81/min |
| AP | Chlorprothixene | Clonazepam (BZD) | 441 ms | 406 ms | 98/min |
| AP | Levomepromazine | Zolpidem (NBZD), alcohol | 428 ms | 387 ms | 112/min |
| AP | Quetiapine, Prothipendyl | Zolpidem (NBZD), alcohol | 435 ms | 408 ms | 88/min |
| AP | Quetiapine | 469 ms | 440 ms | 89/min |
AD, antidepressant; AP, antipsychotic; QTc-B, QT interval – Bazett’s correction; QTc-F, QT interval – Fridericia’s correction; HR, heart rate; SSRI, selective serotonin reuptake inhibitor; NaSSA, noradrenergic and specific serotonergic antidepressant; NDRI, noradrenaline dopamine reuptake inhibitor; SNRI, (selective) serotonin norepinephrine reuptake inhibitor; BZD, benzodiazepine; AC, anticonvulsants, H1RB, H1 receptor blocker; AB, antibiotic; NSAID, nonsteroidal anti-inflammatory drug; ADM, antidiabetic medication; CaA, calcium antagonist; ACE-I, ACE inhibitor; AN, anesthetic; PPI, proton pump inhibitor; FD, fibrate drug; NBZD, non-benzodiazepine).
FIGURE 2Categories and shares of all substances utilized for overdosing. (AD/AP = antidepressants/antipsychotics).
FIGURE 3Median values and percentiles (box plots) of the QTc-B and QTc-F data set in the AD/AP group and both control groups.